Stocks were indicated to open lower on Monday, but this is after a three-week rally. Investors now have to wonder if the theme of buying every dip is back in vogue, after the first six weeks of 2016 was just a chance to sell into every rally.

24/7 Wall St. reviews dozens of analyst reports each morning of the week. The goal is to find new investing and trading ideas for its readers. Some analyst reports cover stocks to buy, and others cover stocks to sell or to avoid.

These are the top analyst upgrades, downgrades and initiations seen from Monday, March 7, 2016.

Enbridge Inc. (NYSE: ENB) was started as Buy at Canaccord Genuity. It closed most recently at $36.70, has a consensus analyst price target of $41.31 and has a 52-week trading range of $27.43 to $54.43.

Micron Technology Inc. (NASDAQ: MU) was downgraded to Reduce from Neutral and the price target was cut to $8 from $12 (versus an $11.88 prior close) at Nomura. Micron has a consensus price target of $15.88 and a 52-week range of $9.31 to $29.78.

Sun Life Financial Inc. (NYSE: SLF) was started as Overweight at Barclays. Its shares closed at $30.44. The consensus price target is $33.87, and the 52-week range is $25.31 to $35.13.

Starbucks Corp. (NASDAQ: SBUX) was reiterated as Buy with a $70 price target (versus a $58.70 close) at Jefferies. The firm said that technology continues to be driver, but the mobile order and pay and rewards plans are driving core beverage growth.

Stratasys Ltd. (NASDAQ: SSYS) was downgraded to Underweight from Neutral with a $22 price target (versus a $27.64 close) at JPMorgan. The stock has a consensus price target of $25.21 and a 52-week range of $14.48 to $63.31. This valuation downgrade follows a Stratasys rally of 12.7% after posting a small loss and beating revenues with better guidance.

Wynn Resorts Ltd. (NASDAQ: WYNN) was raised to Buy from Neutral at UBS. The stock closed at $85.44 and has a consensus price target of $76.75 and a 52-week range of $49.95 to $136.93.

You can follow @Jonogg if you wish for the analyst reports and daily research and market calls to appear directly on your Twitter feed.

Other key analyst upgrades and downgrades this Monday were in the following:
AbbVie Inc. (NYSE: ABBV) was maintained as Buy at Goldman Sachs, but the company was removed from the Conviction Buy List and the price target was cut to $68 from $80.

AveXis Inc. (NASDAQ: AVXS) was started as Buy with a $27 price target (versus a $19.67 close) at Jefferies.

Bancolombia S.A. (NYSE: CIB) was raised to Outperform from Neutral at Credit Suisse.

Cardinal Health Inc. (NYSE: CAH) already was rated as Buy but was added to the prized Conviction Buy List at Goldman Sachs.

Carmike Cinemas Inc. (NASDAQ: CKEC) was downgraded to Hold from Buy at Topeka Capital Markets. Wedbush Securities also downgraded it to Neutral from Outperform.

Helen of Troy Ltd. (NASDAQ: HELE) was started with a Buy rating and $114 price target (versus a $97.98 close) at Jefferies.

InterContinental Hotels Group PLC (NYSE: IHG) was downgraded to Sell from Neutral at Citigroup.

Kimco Realty Corp. (NYSE: KIM) was downgraded to Hold from Buy at Argus.

Mesoblast Ltd. (NASDAQ: MESO) was downgraded to Neutral from Overweight at JPMorgan.

Proteostasis Therapeutics Inc. (NASDAQ: PTI) was started as Outperform with a $20 price target (versus a $5.56 close) at RBC Capital Markets. It was also started as Buy with a $15 price target at H.C. Wainwright.

Randgold Resources Ltd. (NASDAQ: GOLD) was downgraded to Equal Weight from Overweight at Morgan Stanley.

Regions Financial Corp. (NYSE: RF) was reiterated as Buy with an $11 price target (versus an $8.39 close) at Jefferies.

In case you missed Friday’s top analyst calls, they included Apple, Broadcom, DSW, SBA Communications, Tyson Foods and a dozen or so other companies.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.